THIEL BIO, L.L.C.

Thesis

Thiel Bio, L.L.C. is a venture capital firm dedicated to investing in the biotechnology and life sciences sectors, with a primary focus on early-stage companies, particularly those in Series A and Series B funding rounds. The firm's geographic scope is predominantly the United States, though international investments are also considered. Thiel Bio frequently assumes a lead investor position, reflecting a strategic and hands-on approach. Their investment strategy is rooted in Peter Thiel's philosophy of backing companies with unique insights, proprietary technology, and defensible market positions, aiming for monopolies by identifying and supporting visionary founders who possess a strong conviction to reshape industries. In the biotech domain, this translates to a focus on companies developing innovative therapeutics and technologies that address significant unmet needs, with a noted interest in anti-aging research and the overarching goal of 'defeating aging'. While specific AUM and fund size figures are not publicly disclosed, the firm operates as a venture capital fund and is an Exempt Reporting Adviser (ERA), not currently registered with the SEC. While specific check sizes are not detailed, their involvement in significant funding rounds suggests multi-million dollar investments per deal.

Related lists

• Series A AI investors
• Series A Healthcare investors
• Series B AI investors